Freenome Holdings

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Freenome Holdings sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials 1 currently recruiting 4 completed upper quartile by trial count

Freenome Holdings: 5 sponsored US clinical trials, 1 recruiting.

Freenome Holdings sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is Lung Cancer (Diagnosis), with 1 trials.

Upper-quartile sponsor footprint

Freenome Holdings sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Freenome Holdings pipeline

1 recruiting of 5 indexed (20% open); 4 completed (80%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Lung Cancer (Diagnosis) (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Freenome Holdings: open-pipeline peers nationwide

Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Freenome Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4.95.05.055.05.05.1 0%5%10%15%20%25% Total trials Recruiting share Freenome Holdings4YouandMeAbbott Rapid DxAccess Business GroupAcera SurgicalAlign TechnologyAltruBioAlvernia UniversityAmazentis
Freenome Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Freenome Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this Freenome Holdings page

5 registered trials is a research-attention snapshot, not an endorsement of Freenome Holdings or any single study.

  • 1 of Freenome Holdings's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lung Cancer (Diagnosis) is the condition Freenome Holdings studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer (Diagnosis) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Freenome Holdings pipeline card: 5 registered trials from official public datasets.Report a data error.